117
Views
1
CrossRef citations to date
0
Altmetric
Articles

Antimicrobial efficiency of diorganotin(IV) bis-[3-(4-chlorophenyl)-2-methylacrylate]

, , , , , , , & show all
Pages 3315-3329 | Received 30 Oct 2017, Accepted 17 Jul 2018, Published online: 08 Dec 2018
 

Abstract

Four new diorganotin(IV) carboxylates, [n-Bu2SnL2] (1), [Et2SnL2] (2), [Me2SnL2] (3) and [n-Oct2SnL2] (4), where L = 3-(4-chlorophenyl)-2-methylacrylate, were synthesized and characterized by elemental analysis, FT-IR, multinuclear NMR (1H, 13C, and 119Sn) and X-ray single crystal analysis for 1. A chelating bidentate ligand and six-coordinate tin centers were confirmed in the solid state by IR for all complexes and for 1 by X-ray single crystal analysis. The NMR study has shown a decrease in the coordination number of tin in solution. The complexes were screened for their in vitro antibacterial and antifungal activities. A compromised lipo/hydrophilicity and a diffusion controlled antimicrobial activity was shown by the complexes in the order 1 > 2>3 > 4. Molecular docking studies have shown hydrogen bonding and hydrophobic interactions for 1 with the target proteins of the antimicrobial strains.

Graphical Abstract

Acknowledgements

We are thankful to the Higher Education Commission, Islamabad, Pakistan for the financial support.

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.